| Overview |
| bs-0272R-HRP |
| PBEF1 Polyclonal Antibody, HRP Conjugated |
| WB, IHC-P, IHC-F |
| Human, Mouse, Rat |
| Cow, Pig, Horse, Chicken, Monkey |
| Specifications |
| HRP |
| Rabbit |
| KLH conjugated synthetic peptide derived from human PBEF |
| 301-400/491 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 10135 |
| P43490 |
| Cytoplasm |
| VF; PBEF; PBEF1; VISFATIN; 1110035O14Rik; Nicotinamide phosphoribosyltransferase; NAmPRTase; Nampt; Pre-B-cell colony-enhancing factor 1; Pre-B cell-enhancing factor |
| Catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, an intermediate in the biosynthesis of NAD. It is the rate limiting component in the mammalian NAD biosynthesis pathway. The secreted form behaves both as a cytokine with immunomodulating properties and an adipokine with anti-diabetic properties, it has no enzymatic activity, partly because of lack of activation by ATP, which has a low level in extracellular space and plasma. Plays a role in the modulation of circadian clock function. NAMPT-dependent oscillatory production of NAD regulates oscillation of clock target gene expression by releasing the core clock component: CLOCK-ARNTL/BMAL1 heterodimer from NAD-dependent SIRT1-mediated suppression (By similarity). |
| Application Dilution |
| WB |
1:300-5000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
Powered by Bioz